Clinical Trials Browser

Not yet recruiting × Interventional × Genitourinary × Clear all

NCT07574541 2026-05-27

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Phase 2 Not yet recruiting

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

NCT07594002 2026-05-27

Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy

Phase NA Not yet recruiting

Prostatic Neoplasms, Hot Flashes

NCT07608224 2026-05-27

HOPE-07-MIBC

Phase 2/3 Not yet recruiting

Urinary Bladder Neoplasms

NCT07608718 2026-05-27

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07608848 2026-05-27

DOTA-STR-17126

Phase EARLY_PHASE1 Not yet recruiting

BreastGenitourinary

Breast Neoplasms, Neoplasms, Prostatic Neoplasms

NCT07609225 2026-05-27

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

Phase EARLY_PHASE1 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07045415 2026-05-26

The Effect of Pelvic Floor Muscle Exercises After Radical Prostatectomy

Phase NA Not yet recruiting

Prostatic Neoplasms, Urinary Incontinence

NCT07075705 2026-05-22

Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07495293 2026-05-22

Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT07602101 2026-05-22

Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07593040 2026-05-20

Moonlanding

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07598032 2026-05-20

iCCaRE

Phase 3 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07600554 2026-05-20

SWAP

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT07231627 2026-05-19

AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07412275 2026-05-19

MILA

Phase NA Not yet recruiting

Localised Prostate Cancer

NCT07316686 2026-05-18

Lutécio

Phase 1 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07591701 2026-05-18

Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07592910 2026-05-18

MOMENT

Phase 2 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07593079 2026-05-18

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07594106 2026-05-18

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Phase 1/2 Not yet recruiting

Carcinoma, Renal Cell

NCT07516366 2026-05-15

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07564102 2026-05-15

dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT07590934 2026-05-15

PROSPECTOR

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT07591051 2026-05-15

HARP

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07591467 2026-05-15

CaBRA

Phase 3 Not yet recruiting

Prostatic Neoplasms

NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07587814 2026-05-14

COCORIVO

Phase NA Not yet recruiting

Carcinoma, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Phase 1 Not yet recruiting

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT07574489 2026-05-13

Whole Versus Partial Gland Boost During Prostate SBRT

Phase 2/3 Not yet recruiting

Prostatic Neoplasms

NCT07297667 2026-05-12

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Phase 1 Not yet recruiting

BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT07580651 2026-05-12

(CurieInVivo)

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07577999 2026-05-11

The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy

Phase EARLY_PHASE1 Not yet recruiting

Non-metastatic Bladder Cancer

NCT07578025 2026-05-11

Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Phase 2 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07578324 2026-05-11

TENS 2

Phase NA Not yet recruiting

Pain, Procedural, Agnosia, Disease, Prostatic Neoplasms

NCT07578519 2026-05-11

Radiation Treatment of the Prostate That is Specially Adjusted for Each Person

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07576335 2026-05-08

ROBOPREP

Phase 2 Not yet recruiting

Erectile Dysfunction, Prostatic Neoplasms, Urinary Incontinence

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Phase 2 Not yet recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT07231809 2026-05-06

HIVEC

Phase NA Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma

NCT07568756 2026-05-06

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07569926 2026-05-06

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Phase 4 Not yet recruiting

Prostatic Neoplasms

NCT07570966 2026-05-06

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Not yet recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT07571499 2026-05-06

TRANSCEND-XR

Phase NA Not yet recruiting

Testicular Neoplasms

NCT07567027 2026-05-05

Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)

Phase NA Not yet recruiting

Disease, Prostatic Neoplasms

NCT07567521 2026-05-05

A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT07567846 2026-05-05

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT07568236 2026-05-05

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07037004 2026-05-04

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07223385 2026-05-04

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

Phase 2 Not yet recruiting

Disease, Prostatic Neoplasms

NCT07226713 2026-05-04

POSTPONE

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07548476 2026-05-04

ACE

Phase NA Not yet recruiting

Urinary Bladder Neoplasms, Peripheral Nervous System Diseases